Form 4: Vertex Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals, sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Ourania Tatsis, an executive at Vertex Pharmaceuticals, reported changes in beneficial ownership of the company's common stock.
• On February 14, 2025, 2,293 shares were disposed of at a price of $463.46.
• On February 18, 2025, 244 shares were sold at $455.06.
• These transactions were executed under a company-approved trading plan (Rule 10b5-1) established on February 29, 2024.
• Following these transactions, Ms. Tatsis directly owns 67,695 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating routine stock sales by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often part of pre-arranged trading plans to avoid accusations of insider trading. The market typically views these sales in the context of the executive's overall holdings and the reasons behind the sale (e.g., diversification, personal expenses).

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates

Keywords

Form 4, Beneficial Ownership, VRTX, Vertex Pharmaceuticals, Tatsis Ourania, Stock Sale, Rule 10b5-1, Executive Compensation